Tarsus Pharmaceuticals

Into the unknown: Tarsus’ CEO on its launch strategies in a new disease category
Pharma Voice
Fri, 03/8/24 - 11:01 am
Tarsus Pharmaceuticals
Demodex blepharitis
Xdemvy
FDA clears Tarsus' Xdemvy as first treatment for common eyelid disease
Fierce Pharma
Tue, 07/25/23 - 08:58 pm
Tarsus Pharmaceuticals
Xdemvy
FDA
Demodex blepharitis
Four biotechs and a Matthew Roden-led SPAC price IPOs, raising a combined $528M
Endpoints
Fri, 10/16/20 - 12:16 pm
IPOs
biotech
SPAC
Matthew Roden
Praxis Precision Medicines
Tarsus Pharmaceuticals
Aligos Therapeutics
Kiromic Biopharma
Tumeric Acquisition